利舒脲与左旋多巴联合用于晚期帕金森病。

Lisuride combined with levodopa in advanced Parkinson disease.

作者信息

Lieberman A N, Goldstein M, Leibowitz M, Neophytides A, Gopinathan G, Walker R, Pact V

出版信息

Neurology. 1981 Nov;31(11):1466-9. doi: 10.1212/wnl.31.11.1466.

DOI:10.1212/wnl.31.11.1466

Abstract

Lisuride, a semisynthetic ergoline and potent central dopamine and serotonin agonist, was combined with levodopa in 20 patients with advanced Parkinson disease who were no longer responding satisfactorily to levodopa, including 14 patients with "on-off' phenomena. Every patient who completed the 8-week trial improved significantly (p greater than or equal to 0.01), with a decrease in all symptoms. The mean dose of lisuride was 2.4 mg per day. The dose of levodopa (mg of levodopa in Sinemet) was reduced from 1030 to 920 mg. Among the patients with "on-off' phenomena, there was a significant increase in the time in which they were 'on' (mobile) from 4.6 to 9.6 hours. In 5 of 10 patients who have been on lisuride for at least 1 year, there has been no decline in efficacy.

摘要

利舒脲是一种半合成麦角灵，是强效的中枢多巴胺和血清素激动剂，它与左旋多巴联合用于20例晚期帕金森病患者，这些患者对左旋多巴已不再有令人满意的反应，其中包括14例有“开-关”现象的患者。完成8周试验的每位患者均有显著改善（p≥0.01），所有症状均有所减轻。利舒脲的平均剂量为每日2.4毫克。左旋多巴（信尼麦中的左旋多巴毫克数）的剂量从1030毫克降至920毫克。在有“开-关”现象的患者中，“开”（可活动）的时间从4.6小时显著增加至9.6小时。在服用利舒脲至少1年的10例患者中，有5例疗效未下降。